The Manufacturers Life Insurance Company Invests $205.64 Million in Elanco Animal Health Incorporated $ELAN

The Manufacturers Life Insurance Company acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, Holdings Channel reports. The firm acquired 8,355,772 shares of the company’s stock, valued at approximately $205,636,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Elanco Animal Health in the 2nd quarter worth $1,202,198,000. Peak Retirement Planning Inc. bought a new position in Elanco Animal Health during the fourth quarter valued at about $2,756,000. Norges Bank bought a new position in Elanco Animal Health during the fourth quarter valued at about $32,415,000. Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health during the first quarter worth about $66,390,000. Finally, Sei Investments Co. grew its holdings in Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after acquiring an additional 4,975,721 shares during the period. Institutional investors own 97.48% of the company’s stock.

Insider Activity

In other news, Director Paul Herendeen acquired 10,000 shares of Elanco Animal Health stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $23.68 per share, with a total value of $236,800.00. Following the completion of the purchase, the director owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the acquisition, the chief financial officer owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is owned by company insiders.

Elanco Animal Health Stock Up 1.8%

Shares of Elanco Animal Health stock opened at $24.41 on Tuesday. The stock’s fifty day moving average is $24.56 and its 200-day moving average is $24.00. The firm has a market capitalization of $12.20 billion, a PE ratio of -59.54, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same quarter last year, the company posted $0.26 EPS. Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ELAN. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Citigroup lifted their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. TD Cowen boosted their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, Morgan Stanley increased their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.